# Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons

> **NCT01218113** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 191 (actual)

## Conditions studied

- AIDS

## Interventions

- **BIOLOGICAL:** GSK Biologicals HIV Vaccine 732462
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01218113
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-08
- **Primary completion:** 2012-11-05
- **Final completion:** 2012-11-05
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2018-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218113, "Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01218113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*